Literature DB >> 8301063

Elevated circulating plasma endothelin-1 concentrations in cirrhosis.

S Møller1, C Emmeluth, J H Henriksen.   

Abstract

As endothelin-1 (ET-1), a potent vasoconstricting peptide, may play a role in the circulatory derangement and renal impairment in cirrhosis, the aim of the present study was to investigate plasma concentrations of ET-1 in different vascular beds in relation to clinical and biochemical parameters of liver function. Median brachial venous ET-1 concentrations were substantially higher in patients with cirrhosis (3.40 pg/ml, range: 1.25-7.84, n = 24) than in controls (1.53 pg/ml, range: 0.78-2.12, n = 11) (P < 0.00005). In patients with cirrhosis ET-1 was directly correlated to serum creatinine (r = 0.70, P < 0.0001) and aspartate aminotransferase (r = 0.44, P < 0.03) and negatively correlated to serum sodium (r = -0.58, P < 0.003). In patients who underwent liver vein catheterization (n = 8), no significant differences were found in ET-1 plasma concentration between the liver, renal, or femoral veins on the one hand and the femoral artery on the other (P > 0.1), indicating no major net elimination or release in the liver, kidney or lower limb. A significant negative correlation was found between systolic and diastolic blood pressures on the one hand and circulating ET-1 on the other (r = -0.71, P < 0.05). In conclusion, circulating ET-1 is elevated in cirrhosis and related to markers of systemic circulation and renal function, thus suggesting a role for ET-1 in the circulatory derangement and nephropathy in cirrhosis. Locations of major net elimination or release of ET-1 were not identified.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8301063     DOI: 10.1016/s0168-8278(05)80584-7

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  13 in total

Review 1.  Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension.

Authors:  H Reynaert; M G Thompson; T Thomas; A Geerts
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

Review 2.  The hepatorenal syndrome.

Authors:  L Dagher; K Moore
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

3.  High arterial compliance in cirrhosis is related to low adrenaline and elevated circulating calcitonin gene related peptide but not to activated vasoconstrictor systems.

Authors:  J H Henriksen; S Møller; S Schifter; J Abrahamsen; U Becker
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

4.  Plasma nitrate/nitrite and endothelin-1 in patients with liver cirrhosis.

Authors:  Asli Curgunlu; Pervin Vural; Mukaddes Canbaz; Nilgun Erten; M Akif Karan; Cemil Tascioglu
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

Review 5.  The Molecular Basis of Portal Hypertension.

Authors:  Don C Rockey
Journal:  Trans Am Clin Climatol Assoc       Date:  2017

6.  Endothelin is an important determinant of renal function in a rat model of acute liver and renal failure.

Authors:  R Anand; D Harry; S Holt; P Milner; M Dashwood; D Goodier; M Jarmulowicz; K Moore
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

Review 7.  Stellate cell contraction: role, regulation, and potential therapeutic target.

Authors:  Russell K Soon; Hal F Yee
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

8.  Effects of endothelin-1 on hepatic stellate cell proliferation, collagen synthesis and secretion, intracellular free calcium concentration.

Authors:  Chuan-Yong Guo; Jian-Ye Wu; Yun-Bin Wu; Min-Zhang Zhong; Han-Ming Lu
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

9.  Paracrine renal endothelin system in rats with liver cirrhosis.

Authors:  B Hocher; R Zart; F Diekmann; P Rohmeiss; A Distler; H H Neumayer; C Bauer; P Gross
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

Review 10.  The hepatorenal syndrome.

Authors:  G Van Roey; K Moore
Journal:  Pediatr Nephrol       Date:  1996-02       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.